Shilpa Pharma Lifesciences Unit II Raichur facility clears PMDA Japan GMP inspection
Karnataka: Shilpa Medicare Limited has announced that PMDA, Japan has successfully concluded GMP inspection without any critical/major observation at the company's 100% subsidiary, Shilpa Pharma Lifesciences Limited’s Active Pharmaceutical Ingredient (API) manufacturing facility, Unit II, situated at Raichur in Karnataka state.
The facility has undergone an inspection by PMDA, Japan starting 29th August 2023.
"The inspection has concluded successfully on 1st September 2023 without any critical/major observation," the company stated in a BSE filing. The facility is involved in manufacturing various oncology and non‐oncology APIs.
"The company remains committed to maintain the GMP status and quality standards as per the expectations and standards of Global Regulatory Authorities," Shilpa Medicare stated.
Read also: Shilpa Medicare Raichur facility gets Russian GMP certificate
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.